Using innovative physics, researchers have proposed a system that may one day bring proton therapy, a state-of-the-art cancer treatment method currently available only at a handful of centers, to radiation treatment centers and cancer patients everywhere. Compared to the x rays conventionally used in radiation therapy, protons are potentially more effective, as they can deposit more cell-killing energy in their tumor targets and less in surrounding healthy tissue.
However, to kill tumors, the protons must be accelerated to sufficiently high energies, which currently must be achieved in large, expensive accelerators occupying spaces the size of basketball courts. Thomas Mackie (firstname.lastname@example.org), a professor at the University of Wisconsin and co-founder of the radiation therapy company TomoTherapy, will speak at the AAPM meeting, where he will present a proton-therapy design based on a much smaller device known as a "dielectric wall accelerator" (DWA).
Currently being built as a prototype at Lawrence Livermore National Laboratory, the DWA can accelerate protons to up to 100 million electron volts in just a meter. A two-meter DWA could potentially supply protons of sufficiently high energy to treat all tumors, including those buried deep in the body, while fitting in a conventional radiation treatment room.
The DWA is a hollow tube whose walls consist of a very good insulator (a dielectric). When most of the air is removed from the tube to create a vacuum, the tube can structurally withstand the very high electric-field gradations necessary for accelerating protons to high energies in a short distance.
In addition to its smaller size, a DWA-based proton therapy system would have another benefit: it could vary both proton energy and proton-beam intensity, two variables that cannot both be adjusted at the same time in existing proton-treatment facilities.
Mackie cautions that clinical trials of the system are at least five years away. But if the DWA approach proves feasible, protons may eventually represent a widespread, rather than limited, option for treating cancer. (AAPM Paper TH-C-AUD-9.)